---
source_pdf: "https://drive.google.com/file/d/13wiaQML_BvbXiuR79X64rHsxXycFrm3R/view?usp=drivesdk"
drive_folder: "Portfolio/Prudentia"
type: portfolio
company: Prudentia
ingested: 2025-12-24
original_filename: "Prudentia Sciences Series A.pdf"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/13wiaQML_BvbXiuR79X64rHsxXycFrm3R/view?usp=drivesdk)

## Slide 1: Company Overview

**Prudentia Sciences**
Accelerated Insights, Prudent Decisions

**Company Overview**
**Prudentia Sciences**
**2025**

September 2025 | Confidential - Do Not Distribute | Prudentia Sciences

## Slide 2: Prudentia Sciences is building the future of drug dealmaking

Prudentia Sciences is building the future of drug dealmaking with:
*   AI powered clinical evaluation of drugs
*   Valuation tied to clinical progress and risks

September 2025 | Confidential - Do Not Distribute | Prudentia Sciences | 2

## Slide 3: Team Introductions

### Prudentia Sciences Team

**Sadiqa Mahmood**
CEO & Founder
Ex - Health Catalyst, Broad Institute of Harvard & MIT, Mass General Brigham

**Nate Fox**
Chief Technology Officer
Ex - H1, Ribbon Health, Microsoft

**Sharon Tan**
Scientific Lead
Ex - Ultragenyx, enGene, Enzyvent, Genzyme, Boston Scientific

**Ben Klein**
Head of Partnerships
Ex - Flatiron Health, Optum

**John Reynders, PhD**
Head of Strategy
Ex - Moderna, Alexion, J&J

September 2025 | Confidential - Do Not Distribute | 3

## Slide 4: Scientific Advisory Board and Expert Panel

### Mark Currie, PhD (SAB Chair)
*   Board Director, Ironwood Pharmaceuticals
*   Board Director, Science Exchange
*   Pioneered discovery of drugs like Celebrex, Lunesta, and Linzess

### David Nicholson, PhD
*   Executive Vice President and Chief R&D Officer at Allergan
*   Chief Technology Officer and EVP, R&D at Bayer
*   Pioneered discovery of anti-PD1 cancer drug Keytruda® (pembrolizumab)

### Ana Cristina Puga, MD, PhD
*   Head of Early Development, Sarepta Therapeutics
*   VP, Clinical Development CNS, Bluerock Therapeutics
*   Medical Director, Rare Diseases, Sanofi

### Mary Lynne Hedley
*   Board Member, Eli Lilly and Veeva
*   Venture Partner, Third Rock Ventures
*   Pioneered discovery and approval of Tesaro

### Matt Leoni, MD
*   CMO, Merida Biosciences
*   SVP Global Clinical Development, Cerevel Therapeutics
*   Senior Director, CNS, Global Clinical Development, Otsuka
*   Lead Medical Director, Neuroscience, US Early Development, Novartis

### Stuart Chaffee
*   CEO, QuantX Biosciences
*   Co-Founder and Head of BD, Kymera Therapeutics (IPO)
*   CBO of Affinivax (acquired by GSK)
*   CBO & CFO, Praxis Precision Medicines (IPO)

**Company Logos:**
Lilly, cerevel, NOVARTIS, Otsuka, PRAXIS, KYMERA, MERCK, veeva, abbvie

October 2025 | Confidential - Do Not Distribute | 4

## Slide 5: The Challenge in Drug Transactions across Life Sciences Sector

### Unlocking Value in $1.5T Drug Dealmaking Market

These questions reflect the realities of the current market landscape. At the outset, there are several challenges including:

*   “What is the highest value decision can make for my pipeline?”
*   "How can I beat the competition for the next great asset?"
*   “How do I optimize valuation of my asset?"

*   Immense Capital at Risk
*   Systemic Inefficiencies
*   Data Overload, Insight Scarcity
*   Gap in Valuation and Clinical Risks
*   Lack of Enterprise Tools

September 2025 | Confidential - Do Not Distribute | Prudentia Sciences | 5

## Slide 6: Ideal State

### AI Native Approach for Data Driven Deal Making

*   Accelerate speed to decision – from data room access to submission of a competitive bid.
*   Scale diligence team and deal throughput per year.
*   Ensure no stone left unturned, and quickly identify value driver or risk.
*   Achieve optimal bid based on clinical milestones and risks.

September 2025 | Confidential - Do Not Distribute | Prudentia Sciences | 6

## Slide 7: Prudentia is building scientific due diligence platform for global drug asset transactions

### In just 2 years, we have

| Category                        | Value                | Details                                     |
| :------------------------------ | :------------------- | :------------------------------------------ |
| Drug Assessments                | >70                  | 6 Therapeutic Areas                         |
| End of 2025 Sales               | ~$5m                 | Pharma ACV >$1m, Biotech & VC ACV >$125k    |
| End of 2025 Enterprise Customers | >8                   |                                             |
| Pipeline deal amount            | $17.21m              |                                             |
| Deals in active discussions     | 37                   |                                             |

**Deals in Active Discussions Breakdown:**
*   Biopharma: 14
*   Biotech: 7
*   Investor/VC: 13
*   LS Consulting: 3

Highly active pipeline with significant pharma, biotech & investor interest

## Slide 8: Prudentia is Unleashing a $264m Annual Revenue Opportunity

### Capturing 5% of a $5.3B TAM

**$10.5B TAM**
**Prudentia Platform**
Drug diligence and staging

| Customer Segment         | TAM           | Average Deal Size (ARR)         |
| :----------------------- | :------------ | :------------------------------ |
| 5500 Global Pharma       | $8.25b        | ~$1.5m                          |
| 15,000 Biotech           | $1.87b        | ~$125k                          |
| 455 Financial Institutions\* | $437m         | ~$95k (VCs) - $2m (IB)          |

\*103 VCs + 149 PEs + 203 Investment Banks

August 2025 | Confidential - Do Not Distribute | Prudentia Sciences | 8

## Slide 9: Our Solution

### End-to-End Drug Assessment & Valuation Platform

**Prudentia Sciences Platform Features**
*   Traceable AI
*   SOC 2 Enabled

**Platform Components:**
*   **Prism**
    *   Drug Assessment
*   **Pinnacle**
    *   Value Simulation
*   **Pulse**
    *   Staging of Drugs
*   **Prospect**
    *   Top-of-funnel synthesis
*   **Expert in the loop**

August 2025 | Confidential - Do Not Distribute | Prudentia Sciences | 9

## Slide 10: Prudentia Solutions Mapped to Drug Due Diligence Process

### End-to-End Deal Management, Diligence & Valuation Platform

| Stages   | Activity                                                                                                                                                                                                      | Prudentia Solutions    |
| :------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | :--------------------- |
| Stage I  | **Opportunity Screening and Prioritization**<br>● Dynamic Deal Funnel Management & Opportunity Sizing<br>● On-Strategy Alignment w/ Portfolio Priority                                                        | **Prospect**           |
|          | *(Flow from >1000 Deals (eg. sources from JPM, BIO, etc.) to Prudentia Sciences)*                                                                                                                            |                        |
| Stage II | **Asset Assessment and Valuation**<br>● Domain-Specific Diligence w/ Expert Alignment<br>● Deep Market Review & Optimal Valuation Scenarios<br>● Competitive Landscape Assessment                               | **Prism, Pinnacle & Pattern** |
| Stage III| **Deal Execution and Integration**<br>● Decision Analysis and Governance<br>● Deal Execution and Post-Diligence Integration                                                                                  |                        |
|          | *(Flow to <20 high quality deals -> Deal Executed)*                                                                                                                                                           |                        |

September 2025 | Confidential - Do Not Distribute | Prudentia Sciences | 10

## Slide 11: Success Metrics

### How Our Partners Measure Success

| Previous Timeframe | Prudentia Result | Description                                    |
| :----------------- | :--------------- | :--------------------------------------------- |
| 12 Weeks           | 1 Day            | Accelerated Diligence Cycle                    |
| 2 Weeks            | Instant          | Quick Screening of High Value Opportunities    |
| 5 Weeks            | 1 Hour           | For scientific review, Reduce Diligence Burden and Risk for Transaction Teams |
| 4 Weeks            | Instant          | Rapid Simulation of 100s of Scenarios with Clinical Progress and Risks |

August 2025 | Confidential - Do Not Distribute | Prudentia Sciences | 11

## Slide 12: The Prudentia Advantage

### Accelerate Deal Timelines with Quick Decision Making
*   Rapidly disqualify bad deals
*   Focus on high-potential, transformative opportunities
*   Reduce diligence costs and deploy resources to high-value opportunities

### Dual-Sided Platform Driving Network Effects
*   Uniquely serves both buy-side and sell-side transactions across biotechs, pharma, and investors
*   Creates a powerful network effect and comprehensive market coverage

### From Static Snapshots to Continuous, Contextual Diligence
*   Move beyond static due diligence to an "always on" platform capturing evolving asset value – a critical, unmet need.
*   Contextualize clinical, market, regulatory data sets with the asset information.

Confidential - Do not distribute

## Slide 13: Case Study

### Biotech diligence identified previously unknown risks and drive meaningful NPV impact

**Biotech Drug Assessment with Valuation and Risk Simulation**

**SITUATION**
*   A biotechnology company approached Prudentia Sciences with the need to thoroughly assess their early-stage development asset in the Neurology.
*   The company was pursuing external investment and needed support in staging their asset, identifying potential risks, and driving valuation estimates.

**APPROACH**
*   Company leveraged Prudentia's Prism and Pinnacle solutions to comprehensively assess their asset across multiple indications and understand NPV scenarios based on numerous variables pulled from the diligence.
*   Company integrated their data room directly with Prudentia's solution.

**IMPACT**
*   Prudentia solution identified 2 high-risk safety concerns which were previously unknown by Company. This allowed them to proactively address with supplemental data prior to approaching potential investors, directly impacting their NPV.

**Quote:**
“Prudentia's platform helped us rapidly identify potential NPV-impacting variables within our safety & toxicology profile, and with such speed that we were able to proactively supplement prior to investor presentations.” — CEO, Biotech

Confidential - Do not distribute

## Slide 14: Case Study

### Venture Capital firm identified key value drivers and risks

**Biotech Diligence & Valuation / Risk Simulation**

**SITUATION**
*   A venture capital firm had an influx of potential investment opportunities and needed to rapidly perform an in-depth diligence on one key potential biotech investment - time was a limiting factor.

**APPROACH**
*   Company leveraged Prudentia's Prism to assess biotech asset, including clinical, scientific and commercial components.
*   Company integrated their data room directly with Prudentia's solution (>80 data files)

**IMPACT**
*   Prudentia delivered a comprehensive diligence assessment in <15 minutes upon completion of the data room upload.
*   Prism identified a number of potential risks across key domains such as regulatory and CMC, however ultimately showcased a valuable diligence that enabled the VC firm to move forward with the investment quickly.

**Quote:**
"I wish I had this tool 4-5 months ago, as I was working on a diligence process with several colleagues where we evaluated over 100+ immunology & oncology assets...This would be invaluable for the many other newco/venture teams that are also going through this similar process.” — Partner, VC

Confidential - Do not distribute

## Slide 15: Case Study

### Biopharma addressing major enterprise-wide pain points via AI-powered diligence

**Biotech Diligence & Valuation / Risk Simulation**

**SITUATION**
*   A top 20 global biopharma company engaged with Prudentia to help address key pain points in their pursuit for external innovation - specifically:
    *   Slow diligence process that lacks enterprise technology
    *   Painful stakeholder management process to support diligence completion
    *   Lack of consistent framework for assessing external assets

**APPROACH**
*   Company engaged with Prudentia to address these pain points via Prudentia's enterprise platform (Prospect, Prism, Pinnacle)
*   Prudentia presented holistic enterprise approach:
    *   **Prospect** - help manage influx of top-of-funnel deals to identify potential opportunities for further evaluation
    *   **Prism** - dramatically accelerate scientific, regulatory and commercial diligence from weeks to hours
    *   **Pinnacle** - evaluate potential valuation and risk scenarios based on commercial, regulatory, and scientific findings

**Ongoing**

**Quote:**
“We are constantly chasing internal experts for diligence and continue to run an inefficient process. Prudentia is doing this in minutes and we have full provenance of data.” — VP, BD&L - Top 200 Biopharma

Confidential - Do not distribute

## Slide 16: Competitive Landscape

**Y-axis:**
*   AI-native Platform
*   Tech-enabled Consulting Services
*   Consulting Services

**X-axis:**
*   Market Intelligence
*   Financial Modeling
*   Scientific Assessment
*   Comprehensive Scientific Assessment + Valuation

**Mapping of Competitors on the Landscape:**

| Category                             | Market Intelligence | Financial Modeling | Scientific Assessment | Comprehensive Scientific Assessment + Valuation |
| :----------------------------------- | :------------------ | :----------------- | :-------------------- | :---------------------------------------------- |
| **AI-native Platform**               | Evaluate            | AlphaSense         | Prudentia Sciences    | Prudentia Sciences                              |
|                                      | Clarivate™          |                    |                       |                                                 |
| **Tech-enabled Consulting Services** |                     |                    |                       |                                                 |
| **Consulting Services**              |                     | QLS                |                       | BCG                                             |
|                                      |                     |                    |                       | LEK™                                            |

Confidential - Do Not Distribute | Prudentia Sciences | 16

## Slide 17: Raising $25m

### Use of Proceeds

**Pie Chart Data:**

| Category                | Percentage |
| :---------------------- | :--------- |
| Scale Core Platform     | 35.0%      |
| Build Language Models   | 30.0%      |
| New Solutions           | 20.0%      |
| Expand to China         | 15.0%      |

August 2025 | Confidential - Do Not Distribute | Prudentia Sciences | 17

## Slide 18: Vision

### End to end platform for drug dealmaking

**Stages:**
*   **Staging**
    *   Prepare for evaluation
*   **Diligence**
    *   Clinical assessment
*   **Valuation**
    *   Optimal bid
*   **Deal Execution**
    *   Partnering

August 2025 | Confidential - Do Not Distribute | Prudentia Sciences | 18